Free Trial

Mosaic ImmunoEngineering Q1 2024 Earnings Report

Mosaic ImmunoEngineering logo
$0.84 +0.06 (+7.12%)
As of 04/1/2025 11:52 AM Eastern

Mosaic ImmunoEngineering EPS Results

Actual EPS
-$0.04
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Mosaic ImmunoEngineering Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Mosaic ImmunoEngineering Announcement Details

Quarter
Q1 2024
Time
N/A

Conference Call Resources

Remove Ads

Mosaic ImmunoEngineering Earnings Headlines

Mosaic ImmunoEngineering, Inc. (CPMV)
Mosaic Co.
Here’s How to Claim Your Stake in Elon’s Private Company, xAI
Even though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks like you… To partner with Elon on what he believes will be the biggest AI project of the century… Starting with as little as $500.
See More Mosaic ImmunoEngineering Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Mosaic ImmunoEngineering? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Mosaic ImmunoEngineering and other key companies, straight to your email.

About Mosaic ImmunoEngineering

Mosaic ImmunoEngineering (OTCMKTS:CPMV), a development-stage biotechnology company, focuses on developing and commercializing immunomodulator platform technology for the treatment of cancer and infectious diseases in humans and for veterinary use. Its lead immunotherapy product candidate, MIE-101, a nanoparticle-based treatment derived from cowpea mosaic virus, which is non-infectious in humans and animals. The company was founded in 2020 and is based in Novato, California.

View Mosaic ImmunoEngineering Profile

More Earnings Resources from MarketBeat